Test drug to slow kidney damage in type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This Phase 2 study compares tofogliflozin to metformin to see how well they reduce urine albumin levels (a marker of kidney stress) in people with diabetic kidney disease. You might benefit if your type 2 diabetes is affecting your kidneys despite standard blood-pressure medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes
- You are 20 years old or older
- Your recent A1c (average blood sugar) is between 6.5% and 9.0%
- You have diabetic kidney disease shown by your urine albumin-to-creatinine ratio (UACR) being 30 to under 2000
- Your kidneys are working enough for the study (eGFR 30 or higher)
- You have been on a kidney-protecting blood pressure medicine called a RAS inhibitor (ACE/ARB/ARNI or similar) for at least 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding dulaglutide (a weekly injection) to two medications you may already be taking—an SGLT2 inhibitor and finerenone—helps protect your kidneys and controls blood sugar better in people with type 2 diabetes and chronic kidney disease.
This study tests if ganagliflozin, a once-daily pill, can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and manage blood sugar.
This study tests whether a medication called an SGLT2 inhibitor (canagliflozin-like) can help slow kidney disease in people with type 1 diabetes. It may help protect your kidneys if you already have protein in your urine and reduced kidney function.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Hear when a new Metformin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.